International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 32-43 , January 2005

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy

  • Gregory S. Merrick, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Gregory S. Merrick, M.D., Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003-6300, USA. Tel: (304) 243-3490; Fax: (304) 243-5047
    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • Wheeling Jesuit University, Wheeling, WV, USA
    • ,
  • Wayne M. Butler, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • Wheeling Jesuit University, Wheeling, WV, USA
    • ,
  • Kent E. Wallner, M.D.

      Affiliations

    • Puget Sound Health Care System, Group Health Cooperative and University of Washington, Seattle, WA, USA
    • ,
  • Robert W. Galbreath, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • ,
  • Jonathan H. Lief, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • Wheeling Jesuit University, Wheeling, WV, USA
    • ,
  • Zachariah Allen, M.S.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • ,
  • Edward Adamovich, M.D.

      Affiliations

    • Department of Pathology, Wheeling Hospital, Wheeling, WV, USA

Received 11 February 2004 ,Revised 23 April 2004 ,Accepted 3 May 2004.

References 

  1. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643–1652
  2. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. Urology. 2003;62:786–792
  3. Blasko JC, Grimm PD, Sylvester JE, et al.  Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  4. Grimm PD, Blasko JC, Sylvester JE, et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Dattoli M, Wallner K, True L, et al.  Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer. 2003;97:979–983
  6. Sylvester JE, Blasko JC, Grimm PD, et al.  Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer. The Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944–952
  7. Critz FA. A standard definition of disease freedom is needed for prostate cancer (Undetectable prostate specific antigen compared with the American Society for Therapeutic Radiology and Oncology consensus definition). J Urol. 2002;167:1310–1313
  8. Merrick GS, Butler WM, Galbreath RW, et al.  Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:41–48
  9. Merrick GS, Butler WM, Dorsey AT, et al.  Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:717–724
  10. Merrick GS, Butler WM, Dorsey AT, et al.  The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol. 2001;7:233–240
  11. Merrick GS, Butler WM, Wallner KE, et al.  Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:E178–E189
  12. Potters L, Cao Y, Calugaru E, et al.  A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  13. Merrick GS, Wallner KE, Butler WM. Patient selection for prostate brachytherapy. More myth than fact. Oncology. 2004;18:445–452
  14. Blasko JC, Grimm PD, Sylvester JE, et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273–278
  15. Nag S, Beyer D, Friedland J, et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  16. Lee L, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444–452
  17. Barker J, Wallner K, Merrick G. Hematuria after prostate brachytherapy. Urology. 2003;61:408–411
  18. Merrick GS, Butler WM, Wallner KE, et al.  Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:454–461
  19. Merrick GS, Butler WM, Wallner KE. Late rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;57:42–48
  20. Merrick GS, Butler WM, Galbreath RW, et al.  Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;52:893–902
  21. Merrick GS, Butler WM, Lief JH, et al.  Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Cancer J. 2002;8:322–327
  22. Merrick GS, Butler WM, Galbreath RW, et al.  Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?. BJU Int. 2003;91:23–29
  23. Martinez AA, Gustafson F, Gonazalez J, et al.  Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316–327
  24. Merrick GS. Prostate brachytherapy (The shrinking role of hormonal therapy). Brachytherapy. 2003;2:2–4
  25. Potters L, Torre T, Ashley R, et al.  Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187–1192
  26. Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. Oncology. 2003;17:52–62
  27. Merrick GS, Butler WM, Farthing WH, et al.  The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int. 1998;14:112–121
  28. Nath R, Anderson LL, Luxton G, et al.  Dosimetry of interstitial brachytherapy sources (Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43). Med Phys. 1995;22:209–234
  29. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy (Rationale, design and evaluation). Tech Urol. 2000;6:78–84
  30. Merrick GS, Butler WM, Dorsey AT, et al.  Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215–220
  31. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  32. Davis BJ, Pisansky TM, Wilson TM, et al.  The radial distance of extraprostatic extension of prostate carcinoma (Implications for prostate brachytherapy). Cancer. 1999;85:2630–2637
  33. Sohayda C, Kupelian PA, Levin HS, et al.  Extent of extracapsular extension in localized prostate cancer. Urology. 2000;55:382–386
  34. Partin AW, Mangold LA, Lamm DM, et al.  Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843–848
  35. Roach M, DeSilvio M, Lawton C, et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression (Radiation Therapy Oncology Group 9413). J Clin Oncol. 2003;21:1904–1911
  36. Ghaley M, Wallner K, Merrick G, et al.  The effect of supplemental beam radiation on prostate brachytherapy-related morbidity (Morbidity outcomes from two prospective randomized multicenter trials). Int J Radiat Oncol Biol Phys. 2003;55:1288–1293
  37. Prestidge BR, Sanda M, Bice W, et al. RTOG 0232: A phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma. Accessed at www.rtog.org
  38. Hinerman-Mulroy A, Merrick GS, Butler WM, et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2004;59:1367–1382
  39. Merrick GS, Butler WM, Wallner KE, et al.  The influence of hormonal therapy on late rectal function following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;58:68–74

PII: S0360-3016(04)00778-3

doi: 10.1016/j.ijrobp.2004.05.003

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 32-43 , January 2005

Article Tools

* Image Usage & Resolution